Oral insulin ( <scp>ORMD</scp> ‐0801) in type 2 diabetes mellitus: A <scp>dose‐finding 12‐week</scp> randomized <scp>placebo‐controlled</scp> study

Oral insulin (ORMD-0801) induced greater reductions in HbA1c when compared to placebo, and was safe and well tolerated in individuals with uncontrolled T2DM. The efficacy and safety findings support continued development of the 8-mg dose at bedtime, which is currently being evaluated in two Phase 3 trials.